Articles On Dimerix (ASX:DXB)

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Dimerix is looking to raise $12 million to continue its phase 3 Focal Segmental Glomerulosclerosis (FSGS) clinical trial past first interim data. Clinical stage biopharmaceutical company Dimerix (ASX:DXB) has announced a $12 million capita...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Renewable energy technology business Synertec and drug developer Dimerix are expected to return to trading on Wednesday morning, after stitching up equity raisings.

The benchmark kicked off well at +0.8% before deflating to finish on +0.4% Utilities (+1.21%)win the day, while InfoTech (-1.20%) takes a body blow. Lincoln Minerals (ASX:LML) tops the charts, up 36% for absolutely no reason at all.   Loc...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.  In this episode Tim chats to Nina Webster, CEO & managing direct...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped below the radar today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage t...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Dimerix has welcomed news late last week that the US Food and Drug Administration (FDA) has approved the drug Sparsentan for Immunoglobulin A nephropathy (IgAN) another type of rare (orphan) kidney disease. The company says this approval is...

Dimerix (DXB) is set to pocket $2.8 million as a prepayment of a research and development (R&D) tax incentive claim DX8 penned a funding deal with Radium Capital to gain early access to the equivalent of 80 per cent of its accrued R&...

Dimerix has announced another milestone for its pivotal Phase-3 trial with a positive report on a key review evaluating available study data for participant safety, study conduct and progress. ASX listed biotech Dimerix (ASX:DXB) today con...

Dimerix (ASX:DXB) has announced that an independent Data Safety Monitoring Board (DSMB) has successfully concluded a review of the ACTION3 phase 3 clinical trial. 

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Dimerix (ASX:DXB) has confirmed the outcomes of a meeting with the US FDA to discuss the paediatric plan for its DMX-200 in Focal Segmental Glomerulosclerosis (FSGS) patients under 18 years old.

The US Food and Drug Administration (FDA) has confirmed adolescent children can be recruited to Dimerix’s ACTION3 global Phase 3 Focal Segmental Glomerulosclerosis (FSGS) trial. Dimerix (ASX:DXB) today announced details of a meeting with t...

Dimerix (DXB) receives the green light to include paediatric patients in its ACTION3 study of FSGS The company confirmed the US FDA has recommended the evaluation of DMX200 in adolescent patients aged 12 to 17 years in its phase three st...

Tim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications.   After a rickety year dominated by the interest rate rises we...

Dimerix (ASX:DXB) has confirmed that the recruitment of the first 72 patients in its DMX-200 ACTION3 Phase 3 trial in patients with FSGS kidney disease has been achieved.

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

New trials confirm Dimerix’s DMX-200 is safe in treating COVID-19 patients, results that are both in line with previous studies and consistent with the existing safety profile already known about the company’s flagship drug in other indicat...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Aussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering some tent pegs into the dirt Thank the heavens, not much has changed since lunchtime   It’s not been a record-breaker by any stretch of the i...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. Pandemic recovery stocks like CTD and sports betting tech Blubet shone, while COVID play JB Hi-Fi continues to show growth. Here’s so...

Finding effective treatments for kidney disease  has become a hot area among pharmaceutical companies globally and Aussie clinical stage biotech Dimerix has become a leader in the race.  With growing rates of kidney disease and the burden...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc...

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment i...

Dimerix (ASX: DXB) says the CLARITY 2.0 investigator-led study of COVID-19 patients has concluded recruitment.

Dimerix (DX8) closes recruitment for its DMX-200 COVID-19 study, led by CLARITY 2.0, early so as to allow for more efficient analyses and reporting The company is trialling its DMX-200 product as a potential new treatment for respiratory c...

Dimerix has announced a second key study for the treatment of Covid-19 has concluded recruitment. Aussie clinical stage biotech Dimerix (ASX:DXB) has announced the  CLARITY  2.0 led study of  Covid-19  patients has concluded recruitment, e...

Dimerix has announced a new patent family application to protect the results from its mouse study of DMX-700 in COPD. Aussie clinical stage biotech Dimerix (ASX:DXB) has just announced a new patent family application to protect the surprisi...

Dimerix (DXB) submits a new patent family application for its flagship DMX-700 used to treat chronic obstructive pulmonary disease The application follows after the company’s recently announced 80 per cent reduction versus control in indu...

Highlights Dimerix has taken a crucial step towards bolstering its IP position. The biopharmaceutical company has announced a new patent family application for DMX-700 for COPD. DMX-700 achieved a statistically significant 80% reducti...

Highlights Dimerix has taken a crucial step towards bolstering its IP position. The biopharmaceutical company has announced a new patent family application for DMX-700 for COPD. DMX-700 achieved a statistically significant 80% reduction v...

Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...